SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.

NanoVibronix Inc

NAOV is trending following the grant of a new U.S. patent for its ENvue Medical subsidiary, which covers systems guiding medical device insertion using electromagnetic positioning. The community is discussing the stock's potential for further gains, consolidation patterns, and key price levels to watch, while also referencing the stock's low float and potential for a short squeeze.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is trending as investors discuss potential short squeezes amidst high short interest and anticipation of upcoming Fed rate decisions. Community members are highlighting institutional accumulation and technical indicators suggesting a breakout. Recent positive analyst ratings and the company's strategic positioning in the mortgage and real estate market with acquisitions like Redfin are also fueling the conversation.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is experiencing significant volatility, driven by speculation around a potential SOL treasury announcement. The community is actively discussing potential price targets and whether the stock is experiencing a pump and dump, while others highlight a possible incoming FDA submission. Some traders are comparing HSDT to other low float runners and weighing the potential for a short squeeze.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as the community discusses the potential impact of Vice President JD Vance hosting a show on the platform and all time high short interest. Chatter revolves around a possible short squeeze, the upcoming Rumble wallet, and the pending Northern Data acquisition. Investors are also weighing the company's ties to figures and events associated with a former U.S. president.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid excitement surrounding its potential role in powering AI data centers and a new partnership with ABB, though some express concern about its high valuation and lack of revenue. Community discussions include potential price targets and comparisons to other nuclear companies, while others point to past news of share offerings as a cautionary sign. The stock's volatile price action is also a hot topic, with some traders looking to capitalize on short-term swings.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

GLUE is trending due to a licensing agreement with Novartis potentially worth billions, leading to significant upfront payments and future royalties. Community members are debating whether to hold for long-term gains or take profits amidst discussions of short squeezes and potential price targets. The overall sentiment is bullish, driven by the news and the potential for substantial financial upside, though some caution against a possible pullback.

Lulu's Fashion Lounge Holdings, Inc. engages in providing an online website for clothing. It offers retailing of women's clothing, shoes, and accessories. The company was founded in 1996 and is headquartered in Chico, CA.

Lulus Fashion Lounge Holdings Inc

LVLU is trending due to recent price movement and community speculation about a potential short squeeze, driven by its ultra-low float and high short interest. Traders are actively discussing technical setups, analyst price targets, and comparing it to other low-float runners. Some are awaiting further catalysts, such as news or filings, to fuel further momentum.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending due to a mix of factors including analyst upgrades and a strategic investment in AI firm Mistral, signaling a move beyond its core semiconductor equipment business. The community is discussing the potential impact of this AI venture and whether ASML can capitalize on the growing AI sector, while others focus on technical analysis, identifying potential breakout patterns and price targets. Despite positive developments, some remain wary, citing the stock's underperformance compared to peers and broader market volatility.

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

AVITA Medical Inc

AVITA Medical (RCEL) is trending following the CE Mark approval for its RECELL GO device, allowing commercialization across Europe and markets recognizing the CE Mark; the community is discussing the expanded market reach and potential revenue growth. Some are highlighting real-world data showing reduced hospital stays and cost savings with RECELL, while others express concerns about cash flow and dilution. Bullish sentiment centers on the company's growth potential in the wound care market and possible takeover.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending with community members discussing the company's AI initiatives and potential robotaxi business, Zoox. Some traders are pointing to technical indicators, looking for entry points, while others express frustration with the stock's recent performance compared to other tech giants. Broader conversations include potential acquisitions, partnerships, and the competitive landscape in cloud services and advertising.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ensysce Biosciences, Inc. (ENSC) traded nearly 11% higher on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ensysce.com/news/press-releases/detail/186/ensysce-biosciences-announces-positive-data-from-opioid">said</a> its PF614-MPAR pain relief medication demonstrated in a study that it can deliver strong relief for severe pain while protecting from the risk of excessive doses.The company completed the first part of its second clinical trial to evaluate PF614-MPAR for overdose protection. It confirmed that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.CEO Bill Schmidt said that the clinical data demonstrates the ability of the company’s Multi-Pill Abuse Resistance (MPAR) platform as a vital tool to limit overdoses from prescription medications.Ensysce said that the maximum amount of oxycodone released from PF614-MPAR when three or more doses were taken at one time was reduced compared to that released following the consumption of the same amount of PF614 alone.The company said that the new data demonstrates overdose protection across the full dosage range of PF614-MPAR, which is planned for commercialization. It added that this analysis will be discussed with the U.S. Food and Drug Administration (FDA) in an upcoming meeting.The company will now continue to enroll for parts 2 and 3 of the clinical trial, which will allow it to perfect a final drug product for commercialization.On Stocktwits, retail sentiment around Ensysce Biosciences jumped nine points in the ‘extremely bullish’ territory while message volume remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:1300/298;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_15_at_1_11_30_PM_png_9a122ca00d.webp" alt="ENSC's Sentiment Meter and Message Volume as of 1:30 p.m. ET on April 14, 2025 | Source: Stocktwits" width="1300" height="298"><figcaption>ENSC's Sentiment Meter and Message Volume as of 1:30 p.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the shares rallying to $6 from their current $2 levels.<stembedurl>https://stocktwits.com/LowFloatSniper/message/611712896</stembedurl><a href="https://stocktwits.com/symbol/ENSC">ENSC stock</a> is down nearly 73% year-to-date and about 78% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/barclays-downgrades-us-auto-sector-owing-to-trump-tariffs/chQRkPFRbOT">Barclays Downgrades US Auto Sector Owing To Trump’s Tariffs: Retail Sentiment Around GM Takes A Plunge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled

The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.

Equity

Ensysce Biosciences (ENSC) Stock Is Down 30% Today: What's Going On?

Ensysce Biosciences shares are trading lower by 30% during Thursday's session. The company announced a $5 million registered direct offering and concurrent private placement.
read more...

Ensysce Biosciences, Inc. (NASDAQ:ENSC) Sees Significant Decrease in Short Interest

Ensysce Biosciences, Inc. (NASDAQ:ENSC - Get Free Report) was the recipient of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 56,500...

Q4 2023 Ensysce Biosciences Inc Earnings Call Transcript

Ensysce Biosciences reports Q4 EPS ($1.13) vs. ($18.30) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024...

Ensysce Biosciences receives positive Nasdaq listing determination

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

SAN DIEGO, CA / ACCESSWIRE / February 27, 2024 / Ensysce Biosciences, Inc. (the 'Company') (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug...

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

~ PF614-MPAR program receives FDA guidance ~SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ('Ensysce' or the 'Company'), a clinical-stage company applying...

Ensysce Biosciences announces publication of clinical bioequivalence manuscript

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.

Ensysce Biosciences Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

ENSC
Ensysce Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ENSC News

ENSC Ensysce Biosciences Inc